Boston Scientific is a medical device company located in Massachusetts, United States, which is part of the Healthcare sector, and is traded under the ticker BSX on the NYSE exchange.
Boston Scientific stock last closed at $95.12, down 0.14% from the previous day, and has increased 39.96% in one year. It has overperformed other stocks in the Medical Devices industry by 0.58 percentage points. Boston Scientific stock is currently +42.4% from its 52-week low of $66.80, and -11.24% from its 52-week high of $107.17.
At the moment, there are 1.48B BSX shares outstanding. The market capitalization of BSX is $140.38B. In the past 24 hours, 6.67M BSX shares were traded.
You will need an online brokerage account to access the NYSE market and buy BSX shares.
In our opinion, eToro is the best stock brokerage. Here's why:
Get $10 towards your purchase of shares by creating an account with eToro today. This offer is only for US users.
Open eToro AccountNow that you've picked the right brokerage, it's time to fill out some personal info so you are able to buy BSX stock today.
Now that you've opened your account on a mobile trading app, you can securely and quickly fund your account:
Watch the walkthrough below if you need help depositing funds into your brokerage account.
Once you have figured out the best place to buy Boston Scientific stock, it's crucial to research their stock before you buy, so you truly understand the risk and opportunity.
WallStreetZen was designed to help everyday investors do more accurate fundamental analysis.
You can see all of the due diligence checks on BSX's stock page.
You can use many financial metrics, analyses, models, and charts to gauge BSX's true value.
Using relative valuations ratios:
You can do additional valuation analysis on BSX's stock here.
Out of 17 Wall Street analysts who monitor BSX, the consensus analyst rating on Boston Scientific is a Strong Buy
Please keep in mind that analyst forecasts are not stock recommendations, nor are they financial advice.
Jayson Bedford, a top 11% analyst from Raymond James maintains BSX with a strong buy rating and raises their BSX price target from $119.00 to $122.00, on Feb 6, 2025.
Raymond James's Jayson Bedford raised their price target on Boston Scientific (NYSE: BSX) by 2.5% from $119 to $122 on 2025/02/06. The analyst maintained their Strong Buy rating on the stock.
Boston Scientific reported its Q4 and FY 2024 earnings.
Bedford called the quarter "stellar."
The analyst detailed that high expectations into the print were exceeded and that management is "playing the guidance game well."
Overall, Bedford summed up, "Boston Scientific has emerged as one of the fastest growing, and most dynamic, companies in Med Tech."
Boston Scientific reported:
For Q4 2024:
For FY 2024:
Management guided:
For Q1 2025:
For FY 2025:
Chairman & CEO Mike Mahoney commented: "2024 was one of the best years in the history of Boston Scientific, fueled by our innovative portfolio, the launch of our FARAPULSE™ Pulsed Field Ablation System as well as significant clinical achievements and commercial excellence across businesses and regions.
"We have a strong foundation for growth, and I am incredibly grateful for our talented global team and the opportunity to continue transforming the lives of millions of patients around the world."
Shagun Singh, a bottom 14% analyst from RBC Capital maintains BSX with a buy rating and raises their BSX price target from $105.00 to $116.00, on Feb 6, 2025.
Larry Biegelsen, a top 13% analyst from Wells Fargo maintains BSX with a strong buy rating and raises their BSX price target from $100.00 to $118.00, on Feb 6, 2025.
Joanne Wuensch, a top 6% analyst from Citigroup maintains BSX with a strong buy rating and raises their BSX price target from $107.00 to $122.00, on Feb 6, 2025.
Patrick Wood, a top 15% analyst from Morgan Stanley maintains BSX with a strong buy rating and raises their BSX price target from $100.00 to $120.00, on Feb 6, 2025.
You can dig deeper into what analysts are forecasting on the Boston Scientific stock forecast page.
Last year, BSX earnings were $1.85B. In the past five year, BSX's earnings have grown by -17.91% per year. This was slower than the Medical Devices industry average of 10.26%.
Last year, BSX revenue was $16.75B. During the past 5 year, BSX's revenue has increased by 9.3% per year. This was slower than the Medical Devices industry average of 9.92%.
Find out more about BSX's earnings and revenue performance here.
In the last 12 months, insiders at BSX have sold more shares than they have bought.
Michael F. Mahoney, Chairman President CEO of BSX, was the latest BSX insider to buy. They bought $970,201.86 worth of BSX stock on Apr 1, 2025.
Dig into more about who owns BSX stock here.
No, Boston Scientific doesn't provide an income stream by paying out dividends.
One of the primary reasons eToro is our favorite brokerage is because of its social trading community.
Click below to see what other traders have to say.
There are two main options:
Press the Open Trade button and eToro will execute your order.
If you want additional info about buying stocks on eToro, click the how to video below:
Now that you own some BSX stock, you'll want to stay up-to-date on your stock purchase.
Start a watchlist to get notified of the latest news about your BSX stock.
To summarize, here are the 6 steps you need to take to buy Boston Scientific stock right now:
If you require a online brokerage, eToro is our favorite venue.
Get Started with eToro TodayIf you want to get the latest scoop on your investment in Boston Scientific, click the button below.